

## Prior Authorization Request Form for Krystexxa

## FAX this completed form to (877) 386-4695

## OR Mail requests to: Envolve Pharmacy Solutions PA Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720

<u></u>	P	1			
I. PROVIDER INFORMATION		II. MEMBER INFORMATION			
Prescriber Name:		Member Name:			
Prescriber Specialty:		Identification #:			
Office Contact Name:		Group #:			
Group Name:		Date of Birth:			
Fax #:		Medication Allergies:			
Phone #:		-			
III. DRUG INFORMATION (One drug request per form)					
Drug name and strength:	Dosage Interval (si	g):		Qty. per Day:	
IV. REQUIRED DOCUMENTION (Detailed medical record documentation demonstrating evidence for each					
item must be submitted with prior authorization request)					
Specify diagnosis & diagnosis code relevant to this request: Dx/Dx Code:					
Does the member have glucose-6-phosphate dehydrogenase deficiency?				Submit documentation of G6PD screening for at risk members	
Krystexxa will not be used concomitantly with oral urate-lowering agents?					
Requests for all non-preferred medications: Does the member have a history of trial and failure of or contraindication or intolerance to the preferred Antihyperuricemics? Refer toYesSubmit documentation of previous trials/failures, contraindications, 					
<ul> <li>If not prescribed by one of the following specialist rheumatologist or endocrinologist, please indicate a specialist consulted:</li> </ul>					
<ul> <li>If requesting for daily quantity exceeding daily limit (Refer to <a href="https://www.dhs.pa.gov/providers/Pharmacy-services/Pages/Quantity-Limits-and-Daily-Dose-Limits.aspx">https://www.dhs.pa.gov/providers/Pharmacy-services/Pages/Quantity-Limits-and-Daily-Dose-Limits.aspx</a>), please provide supporting information:</li> </ul>					
SUBMIT MEDICAL RECORD INFORMATION FOR EACH APPLICABLE ITEM.					
TREATMENT OF CHRONIC GOUT:					
<ul> <li>Member does not have a history of a contradiction to Krystexxa</li> <li>Recent uric acid level above goal based on American College of Rheumatology guidelines:(submit labs)</li> <li>Member was counseled regarding the following:</li> <li>Appropriate dietary and lifestyle modifications</li> <li>Discontinuation of other medications know to precipitate gout attacks</li> </ul>					
FOR USE OF A URIC ACID LOWERING MEDICATION FOR MORE THAN 6 MONTHS:					
Documentation of improvement in disease severity since initiating Krystexxa, as evidenced by:					
IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION :					

Appropriate clinical information to support the request on	Provider Signature:	Date:
the basis of medical necessity must be submitted.		